加速度计衍生活动碎片化作为大脑缩和多发性硬化症残疾进展的预测因素
medRxiv : the preprint server for health sciences
|September 15, 2025
概括
在多发性硬化症 (MS) 患者中,增加活动碎片化预示着更大的残疾和大脑缩. 这种碎片化可能标志着早期的神经衰退,并作为MS进展的关键指标.
科学领域:
- 神经学 神经学
- 生物医学工程 生物医学工程
- 康复科学 康复科学 康复科学
背景情况:
- 活动碎片化,作为中断体力活动的衡量标准,与一般人群的不良健康结果有关.
- 目前尚不清楚其在多发性硬化症 (MS) 的预后价值.
研究的目的:
- 调查MS (PwMS) 患者活动碎片化和神经衰退之间的关联.
- 确定活动碎片化是否预测MS中残疾进展和大脑缩.
主要方法:
- PwMS (n=239) 随着时间的推移使用了手腕加速度计,并定期接受了残疾和MRI评估.
- 活动到静坐的过渡概率 (ASTP) 和静坐到活动的过渡概率 (SATP) 在10个最活跃的小时 (M10) 中计算.
- 统计模型评估了人内和人间对残疾进展和大脑亚结构缩的影响.
主要成果:
- 在人体内增加ASTP斜率 (更大的活动碎片化) 与确认扩展残疾状况表 (EDSS) 加进展的更高风险相关 (HR 1.22).
- 随着时间的推移,活动碎片化的增加也与深灰色物质和胸膜体积的减少有关.
- 对于SATP和这些结果,没有发现任何显著的关联.
结论:
- 活动碎片化的恶化预测MS神经衰退的风险增加.
- 活动分裂可能表明生理储备减少,并作为MS进展的早期标志物.
相关概念视频
Long-term Potentiation
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Long-term Potentiation
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when presynaptic neurons...
Hebbian LTP
LTP can occur when presynaptic neurons...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...


